Cytokinetics Begins ASPEN-HCM Study Evaluating MYQORZO In Adult Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract